These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

179 related articles for article (PubMed ID: 17408841)

  • 1. Type I interferon response in the central nervous system.
    Paul S; Ricour C; Sommereyns C; Sorgeloos F; Michiels T
    Biochimie; 2007; 89(6-7):770-8. PubMed ID: 17408841
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Distinct and nonredundant in vivo functions of IFNAR on myeloid cells limit autoimmunity in the central nervous system.
    Prinz M; Schmidt H; Mildner A; Knobeloch KP; Hanisch UK; Raasch J; Merkler D; Detje C; Gutcher I; Mages J; Lang R; Martin R; Gold R; Becher B; Brück W; Kalinke U
    Immunity; 2008 May; 28(5):675-86. PubMed ID: 18424188
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Type I interferon subtypes produced by human peripheral mononuclear cells from one normal donor stimulated by viral and non-viral inducing factors.
    Palmer P; Tovey MG; Raschilas F; Brassart L; Meritet JF; Porcher R; Lebon P
    Eur Cytokine Netw; 2007 Jun; 18(2):108-14. PubMed ID: 17594944
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Local type I IFN receptor signaling protects against virus spread within the central nervous system.
    Detje CN; Meyer T; Schmidt H; Kreuz D; Rose JK; Bechmann I; Prinz M; Kalinke U
    J Immunol; 2009 Feb; 182(4):2297-304. PubMed ID: 19201884
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Type I interferons potently suppress gene expression following gene delivery using liposome(-)DNA complexes.
    Sellins K; Fradkin L; Liggitt D; Dow S
    Mol Ther; 2005 Sep; 12(3):451-9. PubMed ID: 15950543
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Interferon and the central nervous system.
    Dafny N; Yang PB
    Eur J Pharmacol; 2005 Oct; 523(1-3):1-15. PubMed ID: 16226745
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Type I interferon receptor signalling is induced during demyelination while its function for myelin damage and repair is redundant.
    Schmidt H; Raasch J; Merkler D; Klinker F; Krauss S; Brück W; Prinz M
    Exp Neurol; 2009 Apr; 216(2):306-11. PubMed ID: 19121307
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Type I interferon pathway in CNS homeostasis and neurological disorders.
    Blank T; Prinz M
    Glia; 2017 Sep; 65(9):1397-1406. PubMed ID: 28519900
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Brain heterogeneity leads to differential innate immune responses and modulates pathogenesis of viral infections.
    Zegenhagen L; Kurhade C; Koniszewski N; Överby AK; Kröger A
    Cytokine Growth Factor Rev; 2016 Aug; 30():95-101. PubMed ID: 27009077
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Inhibition of the development of chronic experimental autoimmune encephalomyelitis by laquinimod (ABR-215062) in IFN-beta k.o. and wild type mice.
    Runström A; Leanderson T; Ohlsson L; Axelsson B
    J Neuroimmunol; 2006 Apr; 173(1-2):69-78. PubMed ID: 16472873
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacogenomics of Type I interferon therapy: a survey of response-modifying genes.
    O'Doherty C; Villoslada P; Vandenbroeck K
    Cytokine Growth Factor Rev; 2007; 18(3-4):211-22. PubMed ID: 17540610
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Inborn errors of interferon (IFN)-mediated immunity in humans: insights into the respective roles of IFN-alpha/beta, IFN-gamma, and IFN-lambda in host defense.
    Zhang SY; Boisson-Dupuis S; Chapgier A; Yang K; Bustamante J; Puel A; Picard C; Abel L; Jouanguy E; Casanova JL
    Immunol Rev; 2008 Dec; 226():29-40. PubMed ID: 19161414
    [TBL] [Abstract][Full Text] [Related]  

  • 13. T-helper 17 cells expand in multiple sclerosis and are inhibited by interferon-beta.
    Durelli L; Conti L; Clerico M; Boselli D; Contessa G; Ripellino P; Ferrero B; Eid P; Novelli F
    Ann Neurol; 2009 May; 65(5):499-509. PubMed ID: 19475668
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Human interferons alpha, beta and omega.
    Bekisz J; Schmeisser H; Hernandez J; Goldman ND; Zoon KC
    Growth Factors; 2004 Dec; 22(4):243-51. PubMed ID: 15621727
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Intranasal administration of interferon beta bypasses the blood-brain barrier to target the central nervous system and cervical lymph nodes: a non-invasive treatment strategy for multiple sclerosis.
    Ross TM; Martinez PM; Renner JC; Thorne RG; Hanson LR; Frey WH
    J Neuroimmunol; 2004 Jun; 151(1-2):66-77. PubMed ID: 15145605
    [TBL] [Abstract][Full Text] [Related]  

  • 16. New lessons about old molecules: how type I interferons shape Th1/Th17-mediated autoimmunity in the CNS.
    Prinz M; Kalinke U
    Trends Mol Med; 2010 Aug; 16(8):379-86. PubMed ID: 20591737
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Homeostatic erythropoiesis by the transcription factor IRF2 through attenuation of type I interferon signaling.
    Mizutani T; Tsuji K; Ebihara Y; Taki S; Ohba Y; Taniguchi T; Honda K
    Exp Hematol; 2008 Mar; 36(3):255-64. PubMed ID: 18207304
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Synergistic inhibition of pseudorabies virus replication by porcine alpha/beta interferon and gamma interferon in vitro.
    Yao Q; Qian P; Cao Y; He Y; Si Y; Xu Z; Chen H
    Eur Cytokine Netw; 2007 Jun; 18(2):71-7. PubMed ID: 17594939
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Synergistic activation of interferon-beta gene transcription by the viral FLICE inhibitory protein of Kaposi's sarcoma-associated herpesvirus and type I IFN activators.
    Cloutier N; Grandvaux N; Flamand L
    Eur J Immunol; 2007 Oct; 37(10):2772-8. PubMed ID: 17899551
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Therapeutic role of beta-interferons in multiple sclerosis.
    Javed A; Reder AT
    Pharmacol Ther; 2006 Apr; 110(1):35-56. PubMed ID: 16229894
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.